MEK Inhibition With Trametinib for the treatment of MAP2K1-Mutated Rosai-Dorfman-Destombes Disease Arising from the Nasopharynx in a Paediatric Patient
Paediatrics
MEK Inhibition With Trametinib for the treatment of MAP2K1-Mutated Rosai-Dorfman-Destombes Disease Arising from the Nasopharynx in a Paediatric Patient
Paediatrics

MEK Inhibition With Trametinib for the treatment of MAP2K1-Mutated Rosai-Dorfman-Destombes Disease Arising from the Nasopharynx in a Paediatric Patient

Pediatr Blood Cancer. 2025 Feb 16:e31595. doi: 10.1002/pbc.31595. Online ahead of print.

NO ABSTRACT

PMID:39956937 | DOI:10.1002/pbc.31595